Recombination and Transmission Studies with Influenza Virus.
Abstract
A new recombinant vaccine, X-32, comprised of the hemagglutinin of A/Equi sub 1 virus and the Hong Kong-like neuraminidase of X-31 is in pilot production and is being used to immunize volunteers. This vaccine embodies a new approach to immunization for influenza. The presence in the recombinant virus of only one minor antigen, the neuraminidase, which is relevant to immunization against the Hong Kong virus, provides 'mono-antigenic immunization' which is expected to provide limited and partial protection against the disease. On the basis of animal studies, it is predicted that such immunization will not prevent infection with influenza virus but will prevent the evolution of infection to disease. Thus, the subject so immunized may realize the benefits of immunity engendered by natural infection as well as the partial immunity induced by this method. (Author)
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1971
- Accession Number
- AD0887571
Entities
People
- Edwin D. Kilbourne
Organizations
- Icahn School of Medicine at Mount Sinai